GlassScriptPhysician profile
Baljit Singh
NPI 1487045837
$2,634.95
in general payments reported to CMS, 2019-2025
12 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2023: $213 · 2024: $833 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $506.60 | 2024-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $357.84 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $296.11 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $249.98 | 2024-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $249.74 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.24 | 2021-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $168.17 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $147.42 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Noven Pharmaceuticals, INC. | $124.74 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $121.20 | 2025 | Quviviq |
| Intuitive Surgical, INC. | $93.49 | 2023 | Da Vinci Surgical System |
| Janssen Pharmaceuticals, INC | $82.42 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baljit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.